Meanwhile, subsequent mechanistic investigation identified that KIF15 might act on the classical PI3K/Akt signaling pathway to promote GBC development since treatment with an Akt activator could attenuate the anti-tumor impact induced by KIF15-deficiency [117] (Fig. 6). The gene discussed is AKT1; the disease is neoplasm.